25 XP   0   0   10

Athira Pharma Inc
Buy, Hold or Sell?

Let's analyse Athira together

PenkeI guess you are interested in Athira Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Athira Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Athira Pharma Inc

I send you an email if I find something interesting about Athira Pharma Inc.

Quick analysis of Athira (30 sec.)










What can you expect buying and holding a share of Athira? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.40
Expected worth in 1 year
$0.66
How sure are you?
23.5%

+ What do you gain per year?

Total Gains per Share
$-2.74
Return On Investment
-136.2%

For what price can you sell your share?

Current Price per Share
$2.01
Expected price per share
$1.75 - $2.16
How sure are you?
50%

1. Valuation of Athira (5 min.)




Live pricePrice per Share (EOD)

$2.01

Intrinsic Value Per Share

$-30.60 - $-36.03

Total Value Per Share

$-27.21 - $-32.64

2. Growth of Athira (5 min.)




Is Athira growing?

Current yearPrevious yearGrowGrow %
How rich?$130.1m$269.9m-$99.7m-58.6%

How much money is Athira making?

Current yearPrevious yearGrowGrow %
Making money-$28.9m-$21m-$7.8m-27.1%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Athira (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#334 / 1010

Most Revenue
#868 / 1010

Most Profit
#780 / 1010

Most Efficient
#314 / 1010

What can you expect buying and holding a share of Athira? (5 min.)

Welcome investor! Athira's management wants to use your money to grow the business. In return you get a share of Athira.

What can you expect buying and holding a share of Athira?

First you should know what it really means to hold a share of Athira. And how you can make/lose money.

Speculation

The Price per Share of Athira is $2.01. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Athira.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Athira, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.40. Based on the TTM, the Book Value Change Per Share is $-0.68 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.56 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Athira.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.71-35.4%-0.77-38.2%-0.62-31.0%-0.44-22.1%-0.44-22.1%
Usd Book Value Change Per Share-0.64-31.9%-0.68-34.1%-0.56-27.9%0.209.9%0.209.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.64-31.9%-0.68-34.1%-0.56-27.9%0.209.9%0.209.9%
Usd Price Per Share2.43-2.48-5.67-8.02-8.02-
Price to Earnings Ratio-0.85--0.81--2.45--6.86--6.86-
Price-to-Total Gains Ratio-3.79--3.67--10.81--3.33--3.33-
Price to Book Ratio0.72-0.57-0.77-1.09-1.09-
Price-to-Total Gains Ratio-3.79--3.67--10.81--3.33--3.33-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.01
Number of shares497
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.680.20
Usd Total Gains Per Share-0.680.20
Gains per Quarter (497 shares)-340.2399.31
Gains per Year (497 shares)-1,360.92397.23
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1361-13710397387
20-2722-27320794784
30-4083-4093011921181
40-5444-5454015891578
50-6805-6815019861975
60-8166-8176023832372
70-9526-9537027812769
80-10887-10898031783166
90-12248-12259035753563
100-13609-13620039723960

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%4.012.01.023.5%4.012.01.023.5%4.012.01.023.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%4.012.01.023.5%4.012.01.023.5%4.012.01.023.5%

Fundamentals of Athira

About Athira Pharma Inc

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Fundamental data was last updated by Penke on 2024-04-11 01:18:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Athira Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Athira earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Athira to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Athira Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY--288.3%+288.3%
5Y--449.1%+449.1%
10Y--605.5%+605.5%
1.1.2. Return on Assets

Shows how efficient Athira is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Athira to the Biotechnology industry mean.
  • -17.0% Return on Assets means that Athira generated $-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Athira Pharma Inc:

  • The MRQ is -17.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.0%TTM-15.1%-2.0%
TTM-15.1%YOY-7.5%-7.6%
TTM-15.1%5Y-14.2%-0.9%
5Y-14.2%10Y-14.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.0%-13.3%-3.7%
TTM-15.1%-12.8%-2.3%
YOY-7.5%-11.7%+4.2%
5Y-14.2%-13.9%-0.3%
10Y-14.2%-15.7%+1.5%
1.1.3. Return on Equity

Shows how efficient Athira is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Athira to the Biotechnology industry mean.
  • -21.0% Return on Equity means Athira generated $-0.21 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Athira Pharma Inc:

  • The MRQ is -21.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -17.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.0%TTM-17.6%-3.3%
TTM-17.6%YOY-7.9%-9.7%
TTM-17.6%5Y-7.5%-10.2%
5Y-7.5%10Y-7.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.0%-16.9%-4.1%
TTM-17.6%-16.1%-1.5%
YOY-7.9%-15.1%+7.2%
5Y-7.5%-19.3%+11.8%
10Y-7.5%-20.2%+12.7%

1.2. Operating Efficiency of Athira Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Athira is operating .

  • Measures how much profit Athira makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Athira to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Athira Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY--298.2%+298.2%
5Y--492.1%+492.1%
10Y--632.4%+632.4%
1.2.2. Operating Ratio

Measures how efficient Athira is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Athira Pharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY-3.890-3.890
5Y-5.739-5.739
10Y-7.876-7.876

1.3. Liquidity of Athira Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Athira is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.37 means the company has $5.37 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Athira Pharma Inc:

  • The MRQ is 5.365. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.511. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.365TTM7.511-2.146
TTM7.511YOY21.702-14.191
TTM7.5115Y22.643-15.132
5Y22.64310Y22.6430.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3653.890+1.475
TTM7.5114.173+3.338
YOY21.7025.344+16.358
5Y22.6436.126+16.517
10Y22.6436.448+16.195
1.3.2. Quick Ratio

Measures if Athira is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Athira to the Biotechnology industry mean.
  • A Quick Ratio of 7.14 means the company can pay off $7.14 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Athira Pharma Inc:

  • The MRQ is 7.139. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.136. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.139TTM10.136-2.997
TTM10.136YOY33.685-23.549
TTM10.1365Y32.217-22.081
5Y32.21710Y32.2170.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.1393.514+3.625
TTM10.1363.998+6.138
YOY33.6855.380+28.305
5Y32.2176.105+26.112
10Y32.2176.404+25.813

1.4. Solvency of Athira Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Athira assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Athira to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.19 means that Athira assets are financed with 18.8% credit (debt) and the remaining percentage (100% - 18.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Athira Pharma Inc:

  • The MRQ is 0.188. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.138. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.188TTM0.138+0.049
TTM0.138YOY0.052+0.087
TTM0.1385Y1.236-1.097
5Y1.23610Y1.2360.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1880.339-0.151
TTM0.1380.336-0.198
YOY0.0520.271-0.219
5Y1.2360.366+0.870
10Y1.2360.389+0.847
1.4.2. Debt to Equity Ratio

Measures if Athira is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Athira to the Biotechnology industry mean.
  • A Debt to Equity ratio of 23.1% means that company has $0.23 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Athira Pharma Inc:

  • The MRQ is 0.231. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.163. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.231TTM0.163+0.068
TTM0.163YOY0.055+0.108
TTM0.1635Y0.065+0.098
5Y0.06510Y0.0650.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2310.388-0.157
TTM0.1630.402-0.239
YOY0.0550.335-0.280
5Y0.0650.426-0.361
10Y0.0650.461-0.396

2. Market Valuation of Athira Pharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Athira generates.

  • Above 15 is considered overpriced but always compare Athira to the Biotechnology industry mean.
  • A PE ratio of -0.85 means the investor is paying $-0.85 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Athira Pharma Inc:

  • The EOD is -0.706. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.853. Based on the earnings, the company is expensive. -2
  • The TTM is -0.814. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.706MRQ-0.853+0.147
MRQ-0.853TTM-0.814-0.039
TTM-0.814YOY-2.446+1.632
TTM-0.8145Y-6.863+6.049
5Y-6.86310Y-6.8630.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.706-2.264+1.558
MRQ-0.853-2.629+1.776
TTM-0.814-2.680+1.866
YOY-2.446-4.145+1.699
5Y-6.863-6.257-0.606
10Y-6.863-6.254-0.609
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Athira Pharma Inc:

  • The EOD is -0.732. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.886. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.940. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.732MRQ-0.886+0.153
MRQ-0.886TTM-0.940+0.055
TTM-0.940YOY-3.067+2.127
TTM-0.9405Y-6.572+5.632
5Y-6.57210Y-6.5720.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.732-2.973+2.241
MRQ-0.886-3.333+2.447
TTM-0.940-3.553+2.613
YOY-3.067-5.605+2.538
5Y-6.572-8.376+1.804
10Y-6.572-8.865+2.293
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Athira is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.72 means the investor is paying $0.72 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Athira Pharma Inc:

  • The EOD is 0.592. Based on the equity, the company is cheap. +2
  • The MRQ is 0.715. Based on the equity, the company is cheap. +2
  • The TTM is 0.570. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.592MRQ0.715-0.124
MRQ0.715TTM0.570+0.145
TTM0.570YOY0.770-0.200
TTM0.5705Y1.092-0.522
5Y1.09210Y1.0920.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5921.896-1.304
MRQ0.7152.115-1.400
TTM0.5702.093-1.523
YOY0.7702.884-2.114
5Y1.0923.542-2.450
10Y1.0923.916-2.824
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Athira Pharma Inc.

3.1. Institutions holding Athira Pharma Inc

Institutions are holding 62.855% of the shares of Athira Pharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Perceptive Advisors LLC14.09710.2931540296460568612.6256
2023-12-31Baker Bros Advisors LP8.22880.0872315380700
2023-12-31Vanguard Group Inc4.43150.0001169845300
2023-12-31Propel Bio Management LLC3.89493.0075149279214927920
2023-12-31Simplify Asset Management Inc.3.89490.3252149279200
2023-12-31BML Capital Management LLC3.79462.67691454362-250000-14.6682
2023-09-30Point72 Asset Management, L.P.2.3680.005490755821530.2378
2023-12-31BlackRock Inc1.72906626621740.0263
2023-12-31Millennium Management LLC1.18940.0005455857-286486-38.5921
2023-09-30Pathstone Family Office, LLC1.11020.006642549200
2023-12-31Pathstone Holdings LLC0.97140.00493722963722960
2023-09-30TANG CAPITAL MANAGEMENT LLC0.92030.100535271500
2023-12-31Dimensional Fund Advisors, Inc.0.90490.0003346804-187647-35.1102
2023-12-31Two Sigma Investments LLC0.79340.00173040713702513.8647
2023-12-31GSA Capital Partners LLP0.7850.061530085137991.2789
2023-09-30Jacobs Levy Equity Management, Inc.0.78190.00362996619891249.2715
2023-12-31Two Sigma Advisers, LLC0.77910.0017298600195006.9867
2023-12-31Geode Capital Management, LLC0.73920.000128332700
2023-12-31Laird Norton Tyee Trust Co0.73660.081128230910360057.9713
2023-12-31Renaissance Technologies Corp0.69250.001265400-17500-6.1859
Total 52.84276.658920252773+1994304+9.8%

3.2. Funds holding Athira Pharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Simplify Propel Opportunities ETF3.89494.9263149279200
2024-02-29Vanguard Total Stock Mkt Idx Inv2.92130.00031119637-64020-5.4087
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.17940.001745201800
2024-02-29Fidelity Extended Market Index0.4430.0017169768-823-0.4824
2024-03-28iShares U.S. Small-Cap Eq Fac ETF0.33060.033812670100
2023-12-31Bridgeway Ultra-Small Company0.29060.31231113932780033.2564
2023-12-31Bridgeway Ultra-Small Company Market0.26270.1317100680-1320-1.2941
2024-02-29DFA US Targeted Value I0.23340.00278947300
2023-09-30BlackRock Extended Mkt Composite0.20170.00117729200
2024-03-28iShares Micro-Cap ETF0.19180.02197352635555.0807
2024-03-29Dimensional US Targeted Value ETF0.18010.00196900800
2024-03-31BlackRock Extended Equity Market K0.1760.001367455240.0356
2023-12-31LUNIS Biotech Growth Opp Fd I a0.16185.29536200000
2024-02-29Vifag 2002 SICAV0.15650.36116000000
2024-02-29DFA US Small Cap I0.15290.00155861300
2024-02-29Fidelity Total Market Index0.12580.00024820800
2024-02-29Fidelity Series Total Market Index0.10260.00023932600
2023-12-31CornerCap Fundametrics Small0.09820.06883764800
2023-12-31CornerCap Small-Cap Value Advisor0.09820.06893764800
2024-03-29Avantis US Small Cap Equity ETF0.08890.00933406400
Total 11.290411.2424327250-34784-0.8%

3.3. Insider Transactions

Insiders are holding 2.192% of the shares of Athira Pharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-05Andrew GengosSELL12082.91
2024-01-05Mark James LittonSELL48202.91
2024-01-05Mark WorthingtonSELL24122.91
2023-12-29Perceptive Advisors LlcBUY1639542.38
2023-12-27Perceptive Advisors LlcBUY321342.28
2023-06-07Andrew GengosBUY150003.43
2023-06-05Andrew GengosBUY450003
2023-06-02Andrew GengosBUY200122.82

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Athira Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.641-0.685+7%-0.561-13%0.200-421%0.200-421%
Book Value Per Share--3.3974.442-24%7.044-52%5.689-40%5.689-40%
Current Ratio--5.3657.511-29%21.702-75%22.643-76%22.643-76%
Debt To Asset Ratio--0.1880.138+36%0.052+262%1.236-85%1.236-85%
Debt To Equity Ratio--0.2310.163+42%0.055+318%0.065+256%0.065+256%
Dividend Per Share----0%-0%-0%-0%
Eps---0.712-0.768+8%-0.624-12%-0.444-38%-0.444-38%
Free Cash Flow Per Share---0.686-0.659-4%-0.480-30%-0.379-45%-0.379-45%
Free Cash Flow To Equity Per Share---0.682-0.656-4%-0.473-31%0.222-407%0.222-407%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---36.034--------
Intrinsic Value_10Y_min---30.602--------
Intrinsic Value_1Y_max---2.157--------
Intrinsic Value_1Y_min---2.118--------
Intrinsic Value_3Y_max---7.589--------
Intrinsic Value_3Y_min---7.223--------
Intrinsic Value_5Y_max---14.357--------
Intrinsic Value_5Y_min---13.231--------
Market Cap77036667.000-21%93133881.00094858582.500-2%217408205.750-57%307402679.118-70%307402679.118-70%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.592-21%0.7150.570+25%0.770-7%1.092-34%1.092-34%
Pe Ratio-0.706+17%-0.853-0.814-5%-2.446+187%-6.863+704%-6.863+704%
Price Per Share2.010-21%2.4302.475-2%5.673-57%8.021-70%8.021-70%
Price To Free Cash Flow Ratio-0.732+17%-0.886-0.940+6%-3.067+246%-6.572+642%-6.572+642%
Price To Total Gains Ratio-3.135+17%-3.790-3.667-3%-10.809+185%-3.327-12%-3.327-12%
Quick Ratio--7.13910.136-30%33.685-79%32.217-78%32.217-78%
Return On Assets---0.170-0.151-12%-0.075-56%-0.142-17%-0.142-17%
Return On Equity---0.210-0.176-16%-0.079-62%-0.075-64%-0.075-64%
Total Gains Per Share---0.641-0.685+7%-0.561-13%0.200-421%0.200-421%
Usd Book Value--130188000.000170264000.000-24%269982000.000-52%218026823.529-40%218026823.529-40%
Usd Book Value Change Per Share---0.641-0.685+7%-0.561-13%0.200-421%0.200-421%
Usd Book Value Per Share--3.3974.442-24%7.044-52%5.689-40%5.689-40%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.712-0.768+8%-0.624-12%-0.444-38%-0.444-38%
Usd Free Cash Flow---26293000.000-25264250.000-4%-18402500.000-30%-14513823.529-45%-14513823.529-45%
Usd Free Cash Flow Per Share---0.686-0.659-4%-0.480-30%-0.379-45%-0.379-45%
Usd Free Cash Flow To Equity Per Share---0.682-0.656-4%-0.473-31%0.222-407%0.222-407%
Usd Market Cap77036667.000-21%93133881.00094858582.500-2%217408205.750-57%307402679.118-70%307402679.118-70%
Usd Price Per Share2.010-21%2.4302.475-2%5.673-57%8.021-70%8.021-70%
Usd Profit---27285000.000-28930500.000+6%-21090500.000-23%-16227411.765-41%-16227411.765-41%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.641-0.685+7%-0.561-13%0.200-421%0.200-421%
 EOD+3 -5MRQTTM+9 -20YOY+3 -265Y+3 -2610Y+3 -26

4.2. Fundamental Score

Let's check the fundamental score of Athira Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.706
Price to Book Ratio (EOD)Between0-10.592
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than17.139
Current Ratio (MRQ)Greater than15.365
Debt to Asset Ratio (MRQ)Less than10.188
Debt to Equity Ratio (MRQ)Less than10.231
Return on Equity (MRQ)Greater than0.15-0.210
Return on Assets (MRQ)Greater than0.05-0.170
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Athira Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.665
Ma 20Greater thanMa 502.344
Ma 50Greater thanMa 1002.920
Ma 100Greater thanMa 2002.783
OpenGreater thanClose2.070
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets160,245
Total Liabilities30,057
Total Stockholder Equity130,188
 As reported
Total Liabilities 30,057
Total Stockholder Equity+ 130,188
Total Assets = 160,245

Assets

Total Assets160,245
Total Current Assets154,729
Long-term Assets5,516
Total Current Assets
Cash And Cash Equivalents 90,584
Short-term Investments 56,835
Net Receivables 1,628
Other Current Assets 5,682
Total Current Assets  (as reported)154,729
Total Current Assets  (calculated)154,729
+/-0
Long-term Assets
Property Plant Equipment 4,437
Long-term Assets Other 448
Long-term Assets  (as reported)5,516
Long-term Assets  (calculated)4,885
+/- 631

Liabilities & Shareholders' Equity

Total Current Liabilities28,840
Long-term Liabilities1,217
Total Stockholder Equity130,188
Total Current Liabilities
Short-term Debt 368
Accounts payable 129
Other Current Liabilities 28,343
Total Current Liabilities  (as reported)28,840
Total Current Liabilities  (calculated)28,840
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,217
Long-term Liabilities  (as reported)1,217
Long-term Liabilities  (calculated)1,217
+/- 0
Total Stockholder Equity
Common Stock4
Retained Earnings -309,206
Accumulated Other Comprehensive Income -349
Other Stockholders Equity 439,739
Total Stockholder Equity (as reported)130,188
Total Stockholder Equity (calculated)130,188
+/-0
Other
Capital Stock4
Cash and Short Term Investments 147,419
Common Stock Shares Outstanding 38,110
Liabilities and Stockholders Equity 160,245
Net Debt -88,999
Net Invested Capital 130,188
Net Working Capital 125,889
Property Plant and Equipment Gross 6,771
Short Long Term Debt Total 1,585



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-03-31
> Total Assets 
0
0
2,189
0
85,431
267,939
279,563
369,414
360,124
347,331
332,008
313,002
292,011
274,185
258,153
232,772
208,048
184,700
160,245
160,245184,700208,048232,772258,153274,185292,011313,002332,008347,331360,124369,414279,563267,93985,43102,18900
   > Total Current Assets 
0
0
2,160
86,473
84,973
232,266
192,337
311,568
290,497
238,992
260,799
269,154
255,860
228,972
207,533
192,896
192,133
178,504
154,729
154,729178,504192,133192,896207,533228,972255,860269,154260,799238,992290,497311,568192,337232,26684,97386,4732,16000
       Cash And Cash Equivalents 
0
0
2,056
0
83,666
165,725
60,625
127,823
131,701
107,328
110,537
117,811
95,057
87,049
95,966
105,182
113,628
110,334
90,584
90,584110,334113,628105,18295,96687,04995,057117,811110,537107,328131,701127,82360,625165,72583,66602,05600
       Short-term Investments 
0
0
0
0
0
60,547
124,057
176,367
153,239
128,447
143,222
145,715
157,347
133,913
104,378
80,799
72,462
62,614
56,835
56,83562,61472,46280,799104,378133,913157,347145,715143,222128,447153,239176,367124,05760,54700000
       Net Receivables 
0
0
7
7
7
0
1,300
2,906
2,589
2,079
2,336
2,234
0
1,700
1,227
0
0
0
1,628
1,6280001,2271,70002,2342,3362,0792,5892,9061,300077700
       Other Current Assets 
0
0
97
0
1,300
5,994
7,655
4,472
2,968
1,138
7,040
3,394
3,456
6,310
5,962
6,915
6,043
5,556
5,682
5,6825,5566,0436,9155,9626,3103,4563,3947,0401,1382,9684,4727,6555,9941,30009700
   > Long-term Assets 
0
0
29
0
458
35,673
87,226
57,846
69,627
108,339
71,209
43,848
36,151
45,213
50,620
39,876
15,915
6,196
5,516
5,5166,19615,91539,87650,62045,21336,15143,84871,209108,33969,62757,84687,22635,67345802900
       Property Plant Equipment 
0
0
0
17
17
1,962
3,585
4,324
4,463
4,565
5,217
5,769
5,942
5,877
5,316
5,270
5,006
4,738
4,437
4,4374,7385,0065,2705,3165,8775,9425,7695,2174,5654,4634,3243,5851,9621717000
       Long Term Investments 
0
0
0
0
0
33,656
83,509
53,467
64,939
103,649
65,936
37,644
29,844
39,071
44,829
33,903
10,217
0
0
0010,21733,90344,82939,07129,84437,64465,936103,64964,93953,46783,50933,65600000
       Other Assets 
0
0
0
441
441
34,670
84,577
55
225
4,690
5,273
435
365
265
0
0
692
0
0
00692002653654355,2734,6902255584,57734,670441441000
> Total Liabilities 
0
0
21,912
0
5,512
8,469
5,281
6,197
9,415
11,094
10,924
11,025
11,446
11,936
23,016
21,647
23,069
29,936
30,057
30,05729,93623,06921,64723,01611,93611,44611,02510,92411,0949,4156,1975,2818,4695,512021,91200
   > Total Current Liabilities 
0
0
1,273
5,512
5,512
7,554
4,405
4,497
7,634
9,386
9,292
9,471
9,692
10,264
21,431
20,150
21,662
28,622
28,840
28,84028,62221,66220,15021,43110,2649,6929,4719,2929,3867,6344,4974,4057,5545,5125,5121,27300
       Short-term Debt 
0
0
0
0
0
57
124
200
263
279
288
297
307
316
326
337
347
358
368
3683583473373263163072972882792632001245700000
       Accounts payable 
0
0
421
4,255
4,255
3,872
1,158
1,687
1,166
959
567
1,431
605
751
2,501
892
612
1,711
129
1291,7116128922,5017516051,4315679591,1661,6871,1583,8724,2554,25542100
       Other Current Liabilities 
0
0
852
0
1,257
1,500
3,123
2,610
6,205
8,148
8,437
7,743
8,780
9,197
18,604
18,921
20,703
26,553
28,343
28,34326,55320,70318,92118,6049,1978,7807,7438,4378,1486,2052,6103,1231,5001,257085200
   > Long-term Liabilities 
0
0
20,639
0
1,047
915
876
1,700
1,781
1,708
1,632
1,554
1,754
1,672
1,585
1,497
1,407
1,314
1,217
1,2171,3141,4071,4971,5851,6721,7541,5541,6321,7081,7811,7008769151,047020,63900
       Other Liabilities 
0
0
0
1,047
1,047
0
0
0
0
1,708
0
0
0
0
0
0
0
0
0
0000000001,70800001,0471,047000
       Deferred Long Term Liability 
0
0
0
415
415
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000415415000
> Total Stockholder Equity
0
0
-19,723
0
79,919
259,470
274,282
363,217
350,709
336,237
321,084
301,977
280,565
262,249
235,137
211,125
184,979
154,764
130,188
130,188154,764184,979211,125235,137262,249280,565301,977321,084336,237350,709363,217274,282259,47079,9190-19,72300
   Common Stock
0
0
0
4
2
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4444444444443324000
   Retained Earnings Total Equity00-248,951-219,354-191,534-161,399-141,210-116,875-95,895-79,556-63,882-49,908-41,042000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
7
33
28
37
4
-388
-1,456
-1,925
-2,472
-1,956
-1,029
-939
-678
-349
-349-678-939-1,029-1,956-2,472-1,925-1,456-3884372833700000
   Capital Surplus 
0
0
0
0
0
0
315,288
413,093
414,550
415,785
417,363
420,304
423,696
426,116
428,623
431,504
434,865
0
0
00434,865431,504428,623426,116423,696420,304417,363415,785414,550413,093315,288000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
0
0
1,364
0
105,254
24,861
274,246
413,093
414,550
415,785
417,363
420,304
423,696
426,116
428,623
431,504
434,865
437,359
439,739
439,739437,359434,865431,504428,623426,116423,696420,304417,363415,785414,550413,093274,24624,861105,25401,36400



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-969
Gross Profit-969-969
 
Operating Income (+$)
Gross Profit-969
Operating Expense-126,125
Operating Income-127,094-127,094
 
Operating Expense (+$)
Research Development92,821
Selling General Administrative33
Selling And Marketing Expenses33,271
Operating Expense126,125126,125
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-127,094
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-117,672-136,516
EBIT - interestExpense = -127,094
-117,672
-117,672
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-127,094-117,672
Earnings Before Interest and Taxes (EBITDA)-126,125
 
After tax Income (+$)
Income Before Tax-117,672
Tax Provision-0
Net Income From Continuing Ops-117,672-117,672
Net Income-117,672
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses127,094
Total Other Income/Expenses Net9,4220
 

Technical Analysis of Athira
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Athira. The general trend of Athira is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Athira's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Athira Pharma Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.02 < 2.02 < 2.16.

The bearish price targets are: 2.02 > 1.771 > 1.75.

Tweet this
Athira Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Athira Pharma Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Athira Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Athira Pharma Inc. The current macd is -0.22021271.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Athira price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Athira. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Athira price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Athira Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartAthira Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Athira Pharma Inc. The current adx is 22.98.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Athira shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Athira Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Athira Pharma Inc. The current sar is 2.58382627.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Athira Pharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Athira Pharma Inc. The current rsi is 33.66. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Athira Pharma Inc Daily Relative Strength Index (RSI) ChartAthira Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Athira Pharma Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Athira price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Athira Pharma Inc Daily Stochastic Oscillator ChartAthira Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Athira Pharma Inc. The current cci is -108.16230474.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Athira Pharma Inc Daily Commodity Channel Index (CCI) ChartAthira Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Athira Pharma Inc. The current cmo is -39.17673494.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Athira Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartAthira Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Athira Pharma Inc. The current willr is -98.62068966.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Athira Pharma Inc Daily Williams %R ChartAthira Pharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Athira Pharma Inc.

Athira Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Athira Pharma Inc. The current atr is 0.18914137.

Athira Pharma Inc Daily Average True Range (ATR) ChartAthira Pharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Athira Pharma Inc. The current obv is -22,439,775.

Athira Pharma Inc Daily On-Balance Volume (OBV) ChartAthira Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Athira Pharma Inc. The current mfi is 32.61.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Athira Pharma Inc Daily Money Flow Index (MFI) ChartAthira Pharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Athira Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Athira Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Athira Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.665
Ma 20Greater thanMa 502.344
Ma 50Greater thanMa 1002.920
Ma 100Greater thanMa 2002.783
OpenGreater thanClose2.070
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Athira with someone you think should read this too:
  • Are you bullish or bearish on Athira? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Athira? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Athira Pharma Inc

I send you an email if I find something interesting about Athira Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Athira Pharma Inc.

Receive notifications about Athira Pharma Inc in your mailbox!